SIGA Stock Overview
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States.
SIGA Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.58|
|52 Week High||US$26.99|
|52 Week Low||US$5.84|
|1 Month Change||-34.00%|
|3 Month Change||-8.64%|
|1 Year Change||44.73%|
|3 Year Change||105.44%|
|5 Year Change||225.54%|
|Change since IPO||101.52%|
Recent News & Updates
SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX
SIGA Technologies (NASDAQ:SIGA) notifies that the U.S. Department of Defense awarded a new contract to SIGA for the procurement of up to $10.7M of oral TPOXX, of which $5.1M of oral TPOXX is targeted for delivery in 2022 and the remainder is subject to an option at the sole discretion of the DoD. The contract follows an award made earlier this year for the procurement of $7.4M of oral TPOXX, under which all product is expected to be delivered in 2022. The project work is supported by a separate development contract worth ~$26M. Shares are up 3.12% premarket.
Siga monkeypox therapy undergoes NIH-led late-stage trial
On Friday, the National Institutes of Health (NIH) announced the start of a late-stage clinical trial to test Siga Technologies’ (NASDAQ:SIGA) Tpoxx antiviral pill on monkeypox patients. Tpoxx, approved in the U.S. for related smallpox infection, is also used to treat monkeypox on a case-by-case basis under the FDA's Expanded Access program. The NIH-led trial is expected to enroll 500 patients, both adults and children, who will be randomized to receive Tpoxx, also known as Tecovirimat, and the placebo. The study is designed to measure if Tpoxx recipients heal faster than those who receive the placebo and obtain critical data on optimal dosing and safety for children and pregnant women. Recently, a team of British scientists, who conducted one of the major clinical trials to find COVID-19 therapies, started a similar trial for Tpoxx in the U.K.
Scientists behind key COVID study run monkeypox trial for SIGA therapy
A team of British scientists, who conducted one of the major trials to find COVID-19 therapies, announced a new clinical study on Tuesday to evaluate whether the antiviral tecovirimat developed by SIGA Technologies (NASDAQ:SIGA) is effective against monkeypox. The scientists from Oxford University rose to fame in 2020 after initiating their so-called RECOVERY trial, which initially tested four treatments against COVID-19. Tecovirimat, also known as TPOXX, is currently available in the U.S. as a treatment for smallpox on a case-by-case basis under the FDA's Expanded Access program. The monkeypox trial named PLATINUM is funded by a ~$4.4M grant from the U.K. government. The randomized trial will enroll at least 500 participants who will receive a 14-day course of 600mg tecovirimat twice daily or a matched placebo. Previously, updating on its plans to launch global studies for TPOXX in monkeypox, SIGA (SIGA) said that the first trial sites in the U.K. would be activated this week.
|SIGA||US Pharmaceuticals||US Market|
Return vs Industry: SIGA exceeded the US Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: SIGA exceeded the US Market which returned -22.1% over the past year.
|SIGA Average Weekly Movement||18.7%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SIGA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: SIGA's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
SIGA Technologies Fundamentals Summary
|SIGA fundamental statistics|
Is SIGA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SIGA income statement (TTM)|
|Cost of Revenue||US$37.43m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.98|
|Net Profit Margin||48.69%|
How did SIGA perform over the long term?See historical performance and comparison
Is SIGA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SIGA?
Other financial metrics that can be useful for relative valuation.
|What is SIGA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SIGA's PE Ratio compare to its peers?
|SIGA PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
TARO Taro Pharmaceutical Industries
AVIR Atea Pharmaceuticals
PAHC Phibro Animal Health
SIGA SIGA Technologies
Price-To-Earnings vs Peers: SIGA is good value based on its Price-To-Earnings Ratio (10.8x) compared to the peer average (15.7x).
Price to Earnings Ratio vs Industry
How does SIGA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Earnings vs Industry: SIGA is good value based on its Price-To-Earnings Ratio (10.8x) compared to the US Pharmaceuticals industry average (12.6x)
Price to Earnings Ratio vs Fair Ratio
What is SIGA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||10.8x|
|Fair PE Ratio||18.8x|
Price-To-Earnings vs Fair Ratio: SIGA is good value based on its Price-To-Earnings Ratio (10.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.8x).
Share Price vs Fair Value
What is the Fair Price of SIGA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SIGA ($10.58) is trading below our estimate of fair value ($29.44)
Significantly Below Fair Value: SIGA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is SIGA Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SIGA's earnings are forecast to decline over the next 3 years (-22.2% per year).
Earnings vs Market: SIGA's earnings are forecast to decline over the next 3 years (-22.2% per year).
High Growth Earnings: SIGA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SIGA's revenue is expected to decline over the next 3 years (-7.9% per year).
High Growth Revenue: SIGA's revenue is forecast to decline over the next 3 years (-7.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SIGA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has SIGA Technologies performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SIGA has high quality earnings.
Growing Profit Margin: SIGA's current net profit margins (48.7%) are higher than last year (45.8%).
Past Earnings Growth Analysis
Earnings Trend: SIGA has become profitable over the past 5 years, growing earnings by -6.1% per year.
Accelerating Growth: SIGA's earnings growth over the past year (64.2%) exceeds its 5-year average (-6.1% per year).
Earnings vs Industry: SIGA earnings growth over the past year (64.2%) exceeded the Pharmaceuticals industry 5%.
Return on Equity
High ROE: SIGA's Return on Equity (51.3%) is considered outstanding.
Discover strong past performing companies
How is SIGA Technologies's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SIGA's short term assets ($153.6M) exceed its short term liabilities ($16.7M).
Long Term Liabilities: SIGA's short term assets ($153.6M) exceed its long term liabilities ($3.5M).
Debt to Equity History and Analysis
Debt Level: SIGA is debt free.
Reducing Debt: SIGA currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: SIGA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SIGA has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is SIGA Technologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
|SIGA Technologies Dividend Yield vs Market|
|Company (SIGA Technologies)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.5%|
|Analyst forecast in 3 Years (SIGA Technologies)||4.3%|
Notable Dividend: Unable to evaluate SIGA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SIGA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SIGA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SIGA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SIGA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Phil Gomez (55 yo)
Dr. Phillip Louis Gomez III, also known as Phil, M.D., PhD, has been Chief Executive Officer of SIGA Technologies, Inc. since October 13, 2016 and has been its Director since December 6, 2016. Dr. Gomez wa...
CEO Compensation Analysis
|Phil Gomez's Compensation vs SIGA Technologies Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$844k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$2m||US$820k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$2m||US$796k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$2m||US$773k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$2m||US$750k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$2m||US$163k|
Compensation vs Market: Phil's total compensation ($USD1.69M) is below average for companies of similar size in the US market ($USD4.14M).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
Experienced Management: SIGA's management team is seasoned and experienced (11.6 years average tenure).
Experienced Board: SIGA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|09 Dec 21||SellUS$234,600||James Antal||Individual||30,000||US$7.82|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
SIGA Technologies, Inc.'s employee growth, exchange listings and data sources
- Name: SIGA Technologies, Inc.
- Ticker: SIGA
- Exchange: NasdaqGM
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$772.595m
- Shares outstanding: 73.02m
- Website: https://www.siga.com
Number of Employees
- SIGA Technologies, Inc.
- 31 East 62nd Street
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SIGA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Sep 1997|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.